Showing posts with label cervical cancer. Show all posts
Showing posts with label cervical cancer. Show all posts

Sunday, 22 May 2016

Princess Health and  Conference on cancer-causing HPV in Lexington June 21. Princessiccia

Princess Health and Conference on cancer-causing HPV in Lexington June 21. Princessiccia

The Kentucky Rural Health Association is sponsoring a summit on the human papilloma virus, "HPV - You ARE the Key!" June 21 at the Embassy Suites in Lexington.

The HPV vaccine is nearly 100 percent effective in preventing pre-cancers and noninvasive cervical cancers caused by two strains of the virus, but most parents in Kentucky and the nation are still not getting their adolescents vaccinated. Kentucky falls in the bottom 10 states for HPV vaccination, with 37.5 percent of its girls and 13.3 percent of boys aged 13-17 vaccinated as of 2014.

The conference will host several keynote speakers, including:
  • Kirk Forbes, who co-founded the Kristen Forbes EVE Foundation in honor of his 23-year-old daughter, Kristen Forbes, who passed away after a yearlong battle with HPV caused cervical cancer;
  • Dr. Daron G. Ferris, professor and director of the Gynecologic Cancer Prevention Center at the Medical College of Georgia;
  • Dr. W. Michael Brown, associate director and the director of pediatrics at the Bayfront Family Medicine Residency Program in St. Petersburg, among other positions; and
  • Dr. Alix Casler, medical director of the Department of Pediatrics for Orlando Health Physician Associates, among other positions.
The conference is also sponsored in collaboration with the Kentucky Immunization Program and the Division of Women's Health.

The event will last from 8 a.m. to 5 p.m. June 21 and costs $40 thru June 1, and $55 after that date. Continuing education credits will be offered. Click here to register and here for the draft agenda.

Friday, 15 April 2016

Princess Health and Kentucky is in the bottom 10 states for cancer-preventing HPV vaccination, probably because it has to do with sex. Princessiccia

The human papillomavirus vaccination is nearly 100 percent effective in preventing precancers and noninvasive cervical cancers caused by two strains of the virus, but most parents in Kentucky and the nation are still not getting their adolescents vaccinated.

HPV is a group of more than 150 related viruses, which together are the most common sexually transmitted infections in the U.S.

An estimated 79 million Americans are infected with HPV and about 14 million more become infected each year, according to the federal Centers for Disease Control and Prevention. And while most HPV strains cause no symptoms and go away on their own, 10 percent of HPV infections lead to cancers of the cervix, vagina, vulva, penis, anus and throat.

The HPV vaccination was approved by the federal government 10 years ago and is recommended for all adolescent girls and boys 11 and 12 years old. Nationwide, fewer than half of girls and only one-fifth of boys are getting immunized.

Kentucky falls in the bottom 10 states for HPV vaccinations, with 37.5 percent of its girls and 13.3 percent of boys aged 13 to 17 vaccinated as of 2014.

The vaccine can be given to females as old as 26 and males as old as 21, but early vaccination is important. The vaccine is less effective if a person has already been exposed to the virus, because it works to prevent HPV before exposure, and not to treat existing HPV infections or associated diseases. Vaccinating adolescents better protects them before they are likely to become sexually active and exposed to the virus.

And therein lies the key reason health experts say most parents don't get their children vaccinated and health providers are hesitant to push this potentially life-saving vaccine: It has to do with sex, Michael Ollove reports for Stateline.

But guess what? Almost 42 percent of Kentucky's high-school students say they have had sexual intercourse, and almost one-third of them say they are currently sexually active, according to the 2015 Kentucky Youth Risk Behavior Survey. And, almost 10 percent of the state's middle-school students say they have had sex.

Opponents of the vaccine being given to adolescents argue that it encourages them to engage in sex because it removes the fear of contracting HPV, but at least one study shows no increase in sexual activity in girls who have been immunized, Ollove reports.

Health officials often lament that the vaccine wasn't originally sold to the public as an anti-cancer vaccine rather than one to prevent a sexually transmitted disease, Ollove reports.

�It should have been pushed out as an anti-cancer drug,�Walt Orenstein, a professor of medicine at Emory University and the former director of the National Immunization Program at the CDC, told Ollove. �People didn�t understand why their children needed this drug when they were still years away from being sexually active.�

Ollove notes other reasons for low vaccination rates: Health-care providers often don't stress the importance of the vaccine; many don't promote the vaccine because they aren't comfortable talking about sex with their young patients or their parents; and many providers feel the vaccine is not urgent because most adolescents in middle school are not sexually active. Another barrier is that the the HPV vaccine requires three inoculations over several months; the CDC shows a dramatic drop-off between the first and last doses.

Citing Noel Brewer, who does research on immunizations at the University of North Carolina and has studied parental and provider attitudes toward HPV, Ollove writes, "Contrary to what doctors may believe, parents are interested in the vaccine and a strong recommendation from a physician correlates highly with youngsters getting the full course of vaccinations."

Ollove notes that mandatory HPV immunizations have not proven to be successful. �Mandates are a last resort after you�ve built consensus that they are a good thing to do,� Orenstein told him.

Health policy researchers say that "reminder and recall" notices are the best way to keep patients up to date on vaccinations, and yet this is not a common practice, Ollove reports.

Insurance will cover the cost of the HPV vaccine and the Vaccines for Children Program will cover the vaccine at no cost for children who don't have insurance and are younger than 19. Call 800-232-4636 for more details.

The Kentucky Rural Health Association in collaboration with the Kentucky Immunization Program and the state Division of Women's Health will be hosting Kentucky's HPV Summit, "HPV: You ARE the Key!," at the Embassy Suites in Lexington June 21. The cost is $40 until June 1 and $55 afterward. Click here to register.

Friday, 26 June 2015

Princess Health and Study finds that one dose of HPV vaccine that targets only cervical cancer is as effective as three doses, now recommended.Princessiccia

By Melissa Patrick
Kentucky Health News

A study has found that one dose of the human papillomavirus vaccine Cervarix appears to be as effective in preventing HPV infections that lead to cervical cancer as do three doses, the recommended course of vaccination. Only 25 percent of Kentucky adolescent women initiate the vaccination, and fewer than one in nine of those who do get three does, according to the Kentucky Cancer Consortium.

"Many women around the world and in the U.S. don't get the full three doses that are recommended, so this is promising news," said Elisia Cohen, an associate professor of communication at the University of Kentucky, who does extensive research on community strategies to improve adolescent and adult vaccinations. However, she cautioned that the drug Cervarix is "only 1 percent of the U.S. market" and that the findings from this study do not apply to Gardasil, the drug most commonly used in the U.S.

Dr. Diane Harper of the University of Louisville, one of the researchers, said in a news release, �Kentucky is one of the states that has not had a program in place to make Cervarix available to all of its citizens, and has very low three-dose completion rates of Gardasil.�

Most health departments and physicians choose Gardasil over Cervarix because it protects against four strains of HPV: two strains that cause 70 percent of all cervical cancers and two strains that cause genital warts and oral and anal cancers, concerns for males as well as females. Cervarix only protects against the two strains that cause cervical cancer. "Generally, the thinking is that protection against four strains is better that two," Cohen said.

She said Gardasil 9, which will protect against 90 percent of HPV strains that cause cervical cancer as well as pre-invasive cervical cancer lesions, has just been approved by the U.S. Food and Drug Administration and is going through its labeling process, and will be recommended for both boys and girls.

HPV is the most common sexually transmitted infection in the U.S., affecting an estimated 79 million individuals, according to the federal Centers for Disease Control and Prevention.

The study, published in The Lancet Oncology, analyzed data from two large trials of Cervarix. In the trials, women were randomly chosen to receive three doses of Cervarix or a control vaccine. All of the women were evaluated, regardless of how many doses of the vaccine they received, for the effectiveness of the vaccine for a period of four years. The analysis found that the protection from one dose was similar to that achieved by three doses of the vaccine.

�Knowing that Cervarix offers protection in one dose reassures public health agencies that they are not wasting money when most of their vaccines are given to those who never complete the three-dose series,� the researchers wrote.

The CDC recommends HPV vaccination for girls 11 and 12 years old, and catch-up vaccination for females from 13 to 26. The second dose should be given one to two months after the first injection; the third dose should be administered six months after the first dose.

Tuesday, 22 January 2013

Princess Health and Avoid virus-linked cancers, including cervical cancer, with shots.Princessiccia

Princess Health and Avoid virus-linked cancers, including cervical cancer, with shots.Princessiccia

With a simple vaccine, you can avoid HPV-linked cancer, including cervical cancer and many cancers of the mouth, throat, anus and genitals, which constitute more than 3 percent of all U.S. cancer diagnoses. Vaccination against the human papilloma virus (HPV) thwarts the virus�s spread, wrecks its ability to jump between people and inhibits a virus that in 2009 led to a cancer diagnosis for 30,000 people in the U.S., according to the National Cancer Insititue

HPV infection is common. More than half of women between 14 and 59 catch a genital HPV. Many of these infections are low-risk, but when the body does not sweep out HPV intruders, high-risk HPV infected cells may lead to the unchecked growth of cancerous cells, according to Newswise, a research-reporting service.

HPV is actually a family of more than 150 viruses that infect human skin and mucosa, the moist membranes lining the nostrils, mouth and genital cavities. Two vaccines, Gardasil and Cervarix, prevent people from getting HPV infections by helping the body stockpile a medley of cellular defenses. Gardasil and Cervarix target HPV types 16 and 18, the two responsible for most cervical, anal, genital, and oropharynx cancer.  Blocking infection by types 16 and 18 also fights off other cancers, and the vaccines� protection could last a lifetime. Gardasil also targets types 6 and 11.

It is important to complete the three-dose series for the vaccines; series completion rates are low for people in the Southern states, especially those that are poor and without private insurance, according to Newswise. Scientists are working to make a single vaccine that blocks infection by all HPV types, but today�s vaccines can prevent infection by two of the most common high-risk HPVs and may be the first step toward preventing HPV-linked cancers. (Read more)


Monday, 21 May 2012

Princess Health and HPV-linked cancers on rise, more prevalent in Kentucky.Princessiccia

The human papillomavirus, which is generally blamed for causing cervical cancer, is being linked to the formation of several other kinds of cancer, and Kentuckians are getting these diseases in unusually high numbers, reports Laura Ungar of The Courier-Journal.

HPV is being linked to cancers of the vagina, vulva, penis, anus and lung, as well as the head and neck. "It's turning out to be a pretty bad actor ... an extensive health problem," said Dr. Daniel Metzinger, a gynecological oncologist with University of Louisville Physicians.

Kentucky's rates for HPV-related cancer are among the highest in the country. Part of the reason may be that smoking is a risk factor and Kentucky has the nation's highest smoking rate, Ungar reports. "I'm seeing more of it for sure," said Metzinger. "It used to be a disease we'd see in older people. Now, we see it in younger and younger people."

One way to protect against the virus is to be immunized with the HPV vaccine. A federal committee recommends vaccinating 11- and 12-year-old girls through to women up to age 26. Boys and men should also be immunized from age 11 to age 21. The immunization must occur before the patient is sexually active, since HPV is sexually transmitted.

In 2010, just 49 percent of adolescent girls nationwide received at least the first of the vaccine's three doses, and only a third had gotten all three, which are required for full effectiveness. In Kentucky that year, only 25 percent of adolescent females had gotten the first dose, and fewer than 11 percent have received all three doses, according to Cervical Cancer-Free Kentucky.

National Cancer Institute numbers show more than half of sexually active people are infected with HPV at some point. Usually, it goes away on its own within a few years. "But it can also set the stage for cancer," Ungar reports. "Across the nation, about 26,000 new cancers attributed to HPV occur each year, with 18,000 in women and 8,000 in men." (Read more)